Journal article
Phase 1 Trial Design: Is 3 + 3 the Best?
Abstract
BACKGROUND: Concerns have been recognized about the operating characteristics of the standard 3 + 3 dose-escalation design. Various innovative phase 1 trial designs have been proposed to address the issues and new challenges posed by molecularly targeted agents. However, in spite of these proposals, the conventional design is still the most widely utilized.
METHODS: A review of the literature of phase 1 trials and relevant statistical studies …
Authors
Hansen AR; Graham DM; Pond GR; Siu LL
Journal
Cancer Control, Vol. 21, No. 3, pp. 200–208
Publisher
SAGE Publications
Publication Date
7 2014
DOI
10.1177/107327481402100304
ISSN
1073-2748